PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
Authors
Keywords
ERK1/2, PD-L1, PD-1, PD0325901, NSCLC, Immunotherapy, Targeted therapy, Combination therapy
Journal
Acta Pharmaceutica Sinica B
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-10
DOI
10.1016/j.apsb.2021.03.010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the 1st-line treatment of squamous NSCLC in the U.S.
- (2019) Ralph P Insinga et al. CURRENT MEDICAL RESEARCH AND OPINION
- Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
- (2019) Parisa Malekzadeh et al. JOURNAL OF CLINICAL INVESTIGATION
- MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2/cofilin pathway in NSCLC
- (2019) Meng Xu et al. Molecular Cancer
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity
- (2019) Sangeetha Palakurthi et al. Cancer Immunology Research
- Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
- (2019) Fan Luo et al. Journal for ImmunoTherapy of Cancer
- Association of combined PD ‐L1 expression and tumour‐infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma
- (2019) C. Bence et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
- (2019) Elena Martin-Orozco et al. Frontiers in Immunology
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis
- (2018) Guangzhi Ma et al. CLINICA CHIMICA ACTA
- Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
- (2018) Ioannis Zerdes et al. ONCOGENE
- Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
- (2018) Chee Khoon Lee et al. JAMA Oncology
- Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 in vitro and in vivo
- (2018) Zhiqiang Zhang et al. Acta Pharmaceutica Sinica B
- Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer
- (2018) Jun Zhao et al. ACS Nano
- SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
- (2018) Mingxia Zhao et al. Acta Pharmaceutica Sinica B
- PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
- (2018) Larissa S. Carnevalli et al. Journal for ImmunoTherapy of Cancer
- Secalonic acid D induces cell apoptosis in both sensitive and ABCG2-overexpressing multidrug resistant cancer cells through upregulating c-Jun expression
- (2018) Hong Zhang et al. Acta Pharmaceutica Sinica B
- High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
- (2017) Å. Helland et al. INTERNATIONAL JOURNAL OF CANCER
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas
- (2016) Francesca Mascia et al. INTERNATIONAL JOURNAL OF CANCER
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Lung Cancer Subtypes Generate Unique Immune Responses
- (2016) Stephanie E. Busch et al. JOURNAL OF IMMUNOLOGY
- Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer
- (2016) Kazuhiko Shien et al. LUNG CANCER
- A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
- (2016) Cuihua Wang et al. MEDICINE
- A framework for understanding and targeting residual disease in oncogene-driven solid cancers
- (2016) Trever G Bivona et al. NATURE MEDICINE
- Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes
- (2016) Jenny Aurielle B Babon et al. NATURE MEDICINE
- Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
- (2016) R. D. Dorand et al. SCIENCE
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells
- (2016) Sherif Abdelhamed et al. Journal of Cancer
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFN
- (2014) P.-C. Ho et al. CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
- (2013) Deborah A. Knight et al. JOURNAL OF CLINICAL INVESTIGATION
- Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
- (2013) Silvia C. Formenti et al. JNCI-Journal of the National Cancer Institute
- Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression
- (2013) WANLU LU et al. Oncology Letters
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Sensitivity of Glioblastomas to Clinically Available MEK Inhibitors Is Defined by Neurofibromin 1 Deficiency
- (2012) W. L. See et al. CANCER RESEARCH
- Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway
- (2012) Fabien Zassadowski et al. CELLULAR SIGNALLING
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- (2012) Julian R. Molina et al. MAYO CLINIC PROCEEDINGS
- Human immunodeficiency virus type 1 Tat induces B7-H1 expression via ERK/MAPK signaling pathway
- (2011) Jijing Shi et al. CELLULAR IMMUNOLOGY
- Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
- (2011) B. P. Pollack et al. CLINICAL CANCER RESEARCH
- Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
- (2011) Sergio A. Quezada et al. IMMUNOLOGICAL REVIEWS
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
- (2010) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
- (2009) Ryo Yamamoto et al. CANCER SCIENCE
- Tumour cell survival signalling by the ERK1/2 pathway
- (2008) K Balmanno et al. CELL DEATH AND DIFFERENTIATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started